Drug insight: Renal indications of calcimimetics

Nature Clinical Practice Nephrology

Volumn 2, Issue 6, 2006, Pages 316-325

  Shahapuni, Irina ^a   Monge, Matthieu ^a   Oprisiu, Roxana ^a   Mazouz, Hakim ^a   Westeel, Pierre François ^a   Morinière, Philippe ^a   Massy, Ziad ^a,b   Choukroun, Gabriel ^a   Fournier, Albert ^a  

^a AMIENS UNIVERSITY HOSPITAL   (France)

^b Department of Pharmacology ^*

Author keywords

Calcimimetic; Chronic kidney disease; Cinacalcet; Dialysis; Secondary hyperparathyroidism

Indexed keywords

25 HYDROXYVITAMIN D; CALCIFEDIOL; CALCIMIMETIC AGENT; CALCITRIOL; CALCIUM ACETATE; CALCIUM CARBONATE; CALCIUM PHOSPHATE; CINACALCET; COLESTILAN; ERGOCALCIFEROL; FERRIC CITRATE; FERRIC HYDROXIDE; LANTHANUM CARBONATE; NICOTINAMIDE; NICOTINIC ACID; PARATHYROID HORMONE; PARICALCITOL; PHOSPHATE BINDING AGENT; SEVELAMER; VITAMIN D DERIVATIVE;

BLOOD VESSEL CALCIFICATION; BONE DENSITY; BONE TURNOVER; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DISEASE ASSOCIATION; DRUG COST; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; HYPERCALCEMIA; HYPOCALCEMIA; KIDNEY GRAFT; NAUSEA; NONHUMAN; PARATHYROID CARCINOMA; PARATHYROID HORMONE RELEASE; PARATHYROIDECTOMY; PARESTHESIA; PRIMARY HYPERPARATHYROIDISM; PRIORITY JOURNAL; REVIEW; SECONDARY HYPERPARATHYROIDISM; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT WITHDRAWAL; UREMIA; VOMITING;

CALCIUM; COST-BENEFIT ANALYSIS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; HYPERPARATHYROIDISM, PRIMARY; HYPERPARATHYROIDISM, SECONDARY; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; NAPHTHALENES; PARATHYROID NEOPLASMS; RENAL DIALYSIS;

EID: 33745951256     PISSN: 17458323     EISSN: 17458331     Source Type: Journal    
DOI: 10.1038/ncpneph0191     Document Type: Review

References (54)

1. Hofer AM and Brown EM (2003) Extracellular calcium sensing and signalling. Nat Rev Mol Cell Biol 4: 530-538
2. Nemeth EF et al. (2004) Pharmacodynamics of the type II calcimimetic compound cinacalcet HCl. J Pharmacol Exp Ther 308: 627-635
3. Shahapuni I et al. (2005) How do calcimimetics fit into the management of parathyroid hormone, calcium, and phosphate disturbances in dialysis patients? Semin Dial 18: 226-238
4. Lindberg JS (2005) Calcimimetics: a new tool for management of hyperparathyroidism and renal osteodystrophy in patients with chronic kidney disease. Kidney Int 67: 533-536
5. Block GA et al. (2004) Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med 350: 1516-1525
6. Moe SM et al. (2005) Achieving NKF-K/DOQI bone metabolism and disease treatment goals with cinacalcet HCl. Kidney Int 67: 760-771
7. Malluche M et al. (2004) Cinacalcet HCl reduces bone turn over and bone marrow fibrosa in hemodialysis patients with secondary hyperparathyroidism. In Abstract Book from ERA-EDTA XLI congress: 2004 May 15-18; Lisbon, P218 (M016)
8. Urena P and Torres A (2004) Clinical experience with cinacalcet HCl. Nephrol Dial Transplant 19: V27-33
9. Cunningham J et al. (2005) Effects of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism. Kidney Int 68: 1793-1800
10. Ogata H et al. (2003) Beneficial effects of calcimimetics on progression of renal failure and cardiovascular risk factors. J Am Soc Nephrol 14: 959-967
11. Porsti I et al. (2004) High calcium diet down-regulates kidney angiotensin-converting enzyme in experimental renal failure. Kidney Int 66: 2155-2166
12. Cozzolino M et al. (2003) Sevelamer hydrochloride attenuates kidney and cardiovascular calcifications in long-term experimental uremia. Kidney Int 64: 1653-1661
13. Phan O et al. (2004) Sevelamer prevents accelerated atherosclerosis in apolipoprotein E deficient (apoE-/-) mice with chronic renal failure (CRF) [abstract]. J Am Soc Nephrol 15: 275A (Poster FPO962)
14. Henley C et al. (2005) 1,25 OH vitamin D but not cinacalcet treatment mediates aortic calcification in a rat model of secondary hyperparathyroidism. Nephrol Dial Transplant 20: 1370-1377
15. Haffner D et al. (2005) Systemic cardiovascular disease in uremic rats induced by 1,25(OH)2D3. J Hypertens 23: 1067-1075
16. Fournier A et al. (2004) Cinacalcet HCl reduces parathyroid hormone and calcium phosphorus product regardless of concurrent changes in vitamin D administration. In Abstract Book from ERA-EDTA XLI congress: 2004 May 15-18; Lisbon, 319
17. Mansour J et al. (2003) Calcimetic AMG 073 at 50 and 100 mg per day. Kidney Int 64: 2324-2325
18. Lindberg JS et al. (2003) The calcimimetic AMG 073 reduces parathyroid hormone and calcium x phosphorus in secondary hyperparathyroidism. Kidney Int 63: 248-254
19. Quarles LD et al. (2003) The calcimimetic AMG 073 as a potential treatment for secondary hyperparathyroidism of end-stage renal disease. J Am Soc Nephrol 14: 575-583
20. Chertow GM et al. (2002) Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 62: 245-252
21. Manns B et al. (2004) A systematic review of sevelamer in ESRD and an analysis of its potential economic impact in Canada and the United States. Kidney Int 66: 1239-1247
22. Slatopolsky E and Bricker NS (1973) The role of phosphorus restriction in the prevention of secondary hyperparathyroidism in chronic renal disease. Kidney Int 4: 141-145
23. Charytan C et al. (2005) Cinacalcet hydrochloride is an effective treatment for secondary hyperparathyroidism in patients with CKD not receiving dialysis. Am J Kidney Dis 46: 58-67
24. Mizobuchi M et al. (2004) Calcimimetic compound upregulates decreased calcium-sensing receptor expression level in parathyroid glands of rats with chronic renal insufficiency. J Am Soc Nephrol 15: 2579-2587
25. Ritter CS et al. (2002) Reversal of secondary hyperparathyroidism by phosphate restriction restores parathyroid calcium-sensing receptor expression and function. J Bone Miner Res 17: 2206-2213
26. LaClair RE et al. (2005) Prevalence of calcidiol deficiency in CKD: a cross-sectional study across latitudes in the United States. Am J Kidney Dis 45: 1026-1033
27. Holick BW (2004) The determination of circulating 25-hydroxyvitamin D: no easy task. J Clin Endocrinol Metab 89: 3149-3151
28. 3 and 25(OH) vitamin D3. Kidney Int Suppl 24: S178-S179
29. Hamdy NA et al. (1995) Effect of alfacalcidol on natural course of renal bone disease in mild to moderate renal failure. BMJ 310: 358-363
30. Ritz E et al. (1995) Low-dose calcitriol prevents the rise of 1-84 PTH without affecting serum calcium and phosphate in patients with moderate renal failure. Nephrol Dial Transplant 10: 2228-2234
31. Lafage MH et al. (1992) Ketodiet, physiological calcium intake and native vitamin D improve renal osteodystrophy. Kidney Int 42: 1217-1225
32. Takahashi Y et al. (2004) Nicotinamide suppresses hyperphosphatemia in hemodialysis patients. Kidney Int 65: 1099-1104
33. Capuzzi DM et al. (1998) Efficacy and safety of an extended-release niacin (Niaspan): a long-term study. Am J Cardiol 82: 74U-81U
34. Gale AM for the ENDIT group (2004) European Nicoticotinamide Diabetes Intervention Trial (ENDIT): a randomised controlled trial of intervention before the onset of type I diabetes. Lancet 363: 925-931
35. Rottembourg JB et al. (2005) Thrombocytopenia induced by nicotinamide in hemodialysis patients. Kidney Int 68: 2911-2912
36. Combe C and Aparicio M (1994) Phosphorus and protein restriction and parathyroid function in chronic renal failure. Kidney Int 46: 1381-1386
37. Lafage Proust M et al. (1999) Bone mass and dynamic parathyroid function according to bone histology in non dialyzed uremic patients after long term protein and phosphorus resctriction. J Clin Endocrinol Metab 84: 512-519
38. Evenepoel P et al. (2005) Impact of parathyroidectomy on renal graft function, blood pressure and serum lipids in kidney transplant recipients: a single center study. Nephrol Dial Transplant 20: 1714-1720
39. Kruse AE et al. (2005) The calcimimetic cinacalcet normalizes serum calcium in renal transplant with persistent hyperparathyroidism. Nephrol Dial Transplant 20: 1311-1314
40. Serra AL et al. (2005) Successful treatment of hypercalcemia with cinacalcet in renal transplant recipients with persistent hyperparathyroï dism. Nephrol Dial Transplant 20: 1315-1319
41. Bilezikian J et al. (2002) Summary statement from a workshop asymptomatic primary hyperparathyroidism: a perspective for the 21 st century. J Bone Miner Res 17: N2-N11
42. Souberbielle JC et al. (2003) The use in clinical practice of parathyroid hormone normative values established in vitamin D-sufficient subjects. J Clin Endocrinol Metab 88: 3501-3504
43. Kolta S et al. (2000) Follow-up of individual patients on two DXA scanners of the same manufacturer. Osteoporos Int 11: 709-713
44. Shoback D et al. (2003) The calcimimetic cinacalcet normalizes serum calcium in subjects with primary hyperparathyroidism. J Clin Endocrinol Metab 88: 5644-5649
45. Peacock M et al. (2005) Cinacalcet hydrochloride maintains long-term normocalcemia in patients with primary hyperparathyrodism. J Clin Endocrinol Metab 90: 135-141
46. Khosla S and Melton LR (2002) Fracture risk in primary hyperparathyroidism. J Bone Miner Res 17 (Suppl 2): N103-N107
47. Heaney R (2002) The basis of the post parathyroidectomy increase in bone mass. J Bone Miner Res 17 (Suppl 2): N154-N157
48. Marx S (2003) Familial hypocalciuric hypercalcemia. In Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism, 239-241 (Ed. Favus M) Philadelphia: Lippincott, Williams & Wilkins
49. Collins M et al. (1998) Treatment of hypercalcemia secondary to parathyroid carcinoma with a novel calcimimetic agent. J Clin Endocrinol Metab 83: 1083-1088
50. Pearce S et al. (1996) A familial syndrome of hypocalcemia with hypercalciuria due to mutations in the calcium-sensing receptor. N Engl J Med 335: 1115-1122
51. Peacock M (2002) Normalization of hypercalcemia with calcimimetic AMG073 in a patient with metastatic parathyroid cancer. J Bone Miner Res 17: S381
52. Silverberg S et al. (2003) The effects of cinacalcet HCl (AMG073) on serum calcium levels in patients with parathyroid carcinoma or recurrent primary hyperparathyroidism after parathyroidectomy. J Bone Miner Res 18 (Suppl): S171
53. Amgen Inc. (online 2005) Cinacalcet (Sensipar®): US prescribing information [http://www.sensipar.com] (accessed May 27 2005)
54. Thervet E et al. (2005) Cytochrome P450 3A polymorphisms and immunosuppressive drugs. Pharmacogenomics 6: 37-47